Reprogramming of CD8 T Cells with CXCL12 Signaling Inhibitors
- 专利权人:
- The General Hospital Corporation
- 发明人:
- Mark C. Poznansky
- 申请号：
- US16637972
- 公开号：
- US20200190202A1
- 申请日:
- 2018.08.10
- 申请国别(地区):
- US
- 年份:
- 2020
- 代理人:
- 摘要：
- The present invention relates to methods and compositions for decreasing the level of PD-1 on a CD8+ T cell, converting a CD25+ Foxp3+ regulatory T cell to a CD25−； Foxp3−； helper-like T cell, and reprogramming subpopulations of T cells to a phenotype suitable to enhance an immunotherapy treatment using an inhibitor of CXCL12 signaling.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- COMPOSITION COMPRISING B REGULATORY CELLS
- Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
- Method for ex vivo inducing of lymphocytes with the phenotype CD8+CD25+FOXP3-, lymphocytes induced by this method, to be used in the methods for preventing and treating diseases and the solution of proteins from a parasite from the group of helminths to be used in the method for inducing of lymphocytes with the phenotype CD8+CD25+FOXP3- in an individual who needs this
- PROIZVODNJA I KORIŠTENJE VITRO-SINTETIZIRANE SSRNA ZA UVOĐENJE U ĆELIJE SISAVACA ZA PROIZVODNJU BIOLOŠKOG ILI BIOKEMIJSKOG UČINKA
- Producing human CD34+CD7+CD5+CD1a− progenitor T cells and method of treatment
